Startup profile · funding coverage
RougeTx funding, valuation and investors
Preclinical biotech developing disease-modifying therapies for vascular disorders by targeting pericyte dysfunction.
Keep track of RougeTx
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$58M · October 6, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$58M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Naarden, Netherlands
Investors in latest funding
Lead: BioGeneration Ventures , Angelini Ventures , Kurma Partners
Other: Epidarex Capital , Vesalius Biocapital Partners , ROM Utrecht Region , p53 Invest , Kerna Ventures
Overview
Naarden-based RougeTx is developing potential disease-modifying therapies designed to restore vascular integrity. Its lead program targets hereditary hemorrhagic telangiectasia, while its periSCOPE platform is intended to support additional vascular-disease programs.
Why RougeTx is interesting
RougeTx launched with a large Series A around a specific vascular-biology thesis and a platform intended to extend beyond hereditary hemorrhagic telangiectasia.
Funding history (newest first)
Series A
2026-10-06 $58M- BioGeneration Ventures (lead)
- Angelini Ventures (lead)
- Kurma Partners (lead)
- Epidarex Capital (participant)
- Vesalius Biocapital Partners (participant)
- ROM Utrecht Region (participant)
- p53 Invest (participant)
- Kerna Ventures (participant)
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover RougeTx's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.